JP2012525376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525376A5 JP2012525376A5 JP2012507877A JP2012507877A JP2012525376A5 JP 2012525376 A5 JP2012525376 A5 JP 2012525376A5 JP 2012507877 A JP2012507877 A JP 2012507877A JP 2012507877 A JP2012507877 A JP 2012507877A JP 2012525376 A5 JP2012525376 A5 JP 2012525376A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- colostrum
- subject
- immunoglobulin preparation
- derived immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17292209P | 2009-04-27 | 2009-04-27 | |
| US61/172,922 | 2009-04-27 | ||
| PCT/IL2010/000339 WO2010125565A2 (en) | 2009-04-27 | 2010-04-27 | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012525376A JP2012525376A (ja) | 2012-10-22 |
| JP2012525376A5 true JP2012525376A5 (https=) | 2013-05-30 |
| JP5740390B2 JP5740390B2 (ja) | 2015-06-24 |
Family
ID=42357536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012507877A Expired - Fee Related JP5740390B2 (ja) | 2009-04-27 | 2010-04-27 | 病的障害の治療および／または予防において使用するための抗ｌｐｓ強化免疫グロブリン製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10117930B2 (https=) |
| EP (2) | EP2424890B1 (https=) |
| JP (1) | JP5740390B2 (https=) |
| KR (1) | KR101785120B1 (https=) |
| AU (1) | AU2010243205B2 (https=) |
| BR (1) | BRPI1014774A2 (https=) |
| CA (2) | CA2760096C (https=) |
| DK (1) | DK2424890T3 (https=) |
| EA (1) | EA024697B1 (https=) |
| ES (1) | ES2684696T3 (https=) |
| IL (1) | IL215924B (https=) |
| MX (1) | MX2011011376A (https=) |
| SG (1) | SG175142A1 (https=) |
| WO (1) | WO2010125565A2 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012023051A2 (en) | 2010-08-17 | 2012-02-23 | Immuron Ltd. | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder |
| TW201304786A (zh) * | 2010-10-04 | 2013-02-01 | Immuron Ltd | 使用抗ｌｐｓ配體治療及預防發炎疾病的方法及組合物 |
| MY164281A (en) | 2010-11-23 | 2017-11-30 | Pantheryx Inc | Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications |
| DE102011006781A1 (de) * | 2011-04-05 | 2012-10-11 | Mat-Malta Advanced Technologies Limited | Antikörperprodukt, umfassend n spezifische Antikörper |
| DE102011006809A1 (de) | 2011-04-05 | 2012-10-11 | Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg | Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten |
| MX374963B (es) | 2011-04-29 | 2025-03-06 | Selecta Biosciences Inc | Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos. |
| WO2012171077A1 (en) * | 2011-06-17 | 2012-12-20 | Immuron Limited | Method and composition for treatment or inhibition of mucositis associated with chemotherapy or radiation damage |
| WO2013009843A1 (en) * | 2011-07-11 | 2013-01-17 | Camas Incorporated | Compositions against bacterial toxins |
| AU2013204801B2 (en) | 2012-05-23 | 2014-11-06 | Omniblend Innovation Pty Ltd | Composition and method for management of diabetes or pre-diabetes |
| EP2864346B1 (en) * | 2012-06-21 | 2018-10-17 | Synthon Biopharmaceuticals B.V. | Method of purifying an antibody |
| PL2945651T3 (pl) | 2013-01-17 | 2018-08-31 | Arsanis Biosciences Gmbh | Przeciwciało swoiste wobec E.coli MDR |
| BR122020023215B1 (pt) | 2013-05-03 | 2022-11-22 | Selecta Biosciences, Inc | Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico |
| WO2015063693A1 (en) * | 2013-10-30 | 2015-05-07 | Hadasit Medical Research Services And Development Limited | Anti-lps enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis |
| WO2015117711A1 (en) | 2014-02-06 | 2015-08-13 | Arsanis Biosciences Gmbh | E. coli specific antibody sequences |
| WO2015124769A1 (en) | 2014-02-24 | 2015-08-27 | Glycovaxyn Ag | Novel polysaccharide and uses thereof |
| JP7242180B2 (ja) | 2014-09-07 | 2023-03-20 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物 |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| AU2017260881A1 (en) * | 2016-05-06 | 2018-12-20 | Hadasit Medical Research Services & Development Limited | Hyperimmune colostrum in the modulation and treatment of conditions associated with the mammailan microbiome |
| AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| ES3036482T3 (en) | 2017-03-11 | 2025-09-19 | Cartesian Therapeutics Inc | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| ES3053674T3 (en) | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| CA3105117A1 (en) * | 2018-07-02 | 2020-01-09 | Puretech Lyt, Inc. | Milk vesicles for use in delivering biological agents |
| CN112996808A (zh) * | 2018-10-03 | 2021-06-18 | 埃努贝尔拜欧公司 | 用于治疗动物急性腹泻和肠道感染的组合物和方法 |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| CN113365637A (zh) * | 2018-12-05 | 2021-09-07 | 维京治疗公司 | 用于治疗肝部病症的组合物和方法 |
| WO2020176637A1 (en) | 2019-02-26 | 2020-09-03 | Pantheryx, Inc. | Compositions for management of disorders of the gastrointestinal tract |
| CA3134216A1 (en) | 2019-03-18 | 2020-09-24 | Janssen Pharmaceuticals, Inc. | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
| IL286467B2 (en) | 2019-03-18 | 2026-02-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them |
| AU2020287627A1 (en) | 2019-06-04 | 2021-11-18 | Selecta Biosciences, Inc. | Formulations and doses of PEGylated uricase |
| US20210252149A1 (en) * | 2020-02-19 | 2021-08-19 | Anubis Bio Corporation | Composition and Methods for Treating Infectious Agents Using Pathogen-specific Antibodies |
| AU2021342797B2 (en) | 2020-09-17 | 2024-02-08 | Janssen Pharmaceuticals, Inc. | Multivalent vaccine compositions and uses thereof |
| WO2022221616A1 (en) | 2021-04-16 | 2022-10-20 | Prodigy Biotech | Hyperimmunized egg product for treating or preventing alcoholic liver disease and graft-versus-host disease |
| US20250051426A1 (en) * | 2021-09-30 | 2025-02-13 | Igalphan corporation | Composition containing monoclonal antibody |
| WO2025188199A1 (en) * | 2024-03-06 | 2025-09-12 | Koru Biotech Solutions Limited | Therapeutic and prophylactic agents and related compositions and methods |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH627079A5 (en) | 1977-04-15 | 1981-12-31 | Nestle Sa | Process for preparing a protein concentrate containing immunological factors of milk origin |
| US4550019A (en) | 1978-03-22 | 1985-10-29 | South Africa Inventions Development Corporation | Manufacture and use of fowl egg antibodies |
| JPS58154513A (ja) | 1982-03-09 | 1983-09-14 | Sendai Biseibutsu Kenkyusho | 予防及び治療薬 |
| US4748018A (en) | 1984-02-07 | 1988-05-31 | Stolle Research & Development Corp. | Method of passive immunization of mammals using avian antibody |
| GB9105292D0 (en) * | 1991-03-13 | 1991-04-24 | Sandoz Ltd | Improvements in or relating to organic compounds |
| DE69432309D1 (de) | 1993-09-20 | 2003-04-24 | Anadis Ltd | Verfahren zur herstellung von immunoglobulinen aus colostrum und deren verwendung in pharmazeutischen zusammensetzungen |
| DE4337654C2 (de) | 1993-11-04 | 1996-08-08 | Biotest Pharma Gmbh | Verwendung boviner Kolostralmilch von nicht mit Viren hyperimmunisierten Tieren als Leberschutzpräparat |
| ID26730A (id) | 1998-05-27 | 2001-02-01 | Gemma Biotechnology Ltd | Induksi protein-protein dan peptida-peptida antibiotik oleh lait/scd14-protein |
| DE19830607C2 (de) | 1998-07-09 | 2002-08-01 | Hte Ag The High Throughput Exp | Verfahren zum Nachweis eines Produktes im Abstrom eines katalytischen Materials einer Vielzahl von katalytischen Materialien |
| US20050175597A1 (en) | 2002-03-21 | 2005-08-11 | Rawlin Grant T. | Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment |
| CA2486801A1 (en) | 2002-05-21 | 2003-11-27 | Anadis Ltd | Method of prophylaxis of infection |
| US9701737B2 (en) | 2003-02-19 | 2017-07-11 | Camas, Incorporated | Immunogen adherence and method of making and using same |
| AU2003901008A0 (en) | 2003-03-04 | 2003-03-20 | Anadis Ltd | Composition for the treatment and prevention of bacterial infections |
| WO2006035979A1 (ja) * | 2004-09-29 | 2006-04-06 | Asama Chemical Co., Ltd. | 乳清タンパク、乳由来の抗体または抗体を含む機能性組成物または食品 |
| AU2005306579B2 (en) | 2004-11-22 | 2012-01-19 | Immuron Limited | Bioactive compositions |
| DK2061510T3 (en) * | 2006-08-31 | 2016-09-05 | A C N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust | Treatment and / or prevention of Barrett's esophagus using anti-EphB4 antibody-containing compositions |
| WO2009113065A1 (en) | 2008-03-13 | 2009-09-17 | Hadasit Medical Research Services & Development Ltd. | Immuno-modulating compositions for the treatment of immune-mediated disorders |
| WO2012023051A2 (en) | 2010-08-17 | 2012-02-23 | Immuron Ltd. | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder |
-
2010
- 2010-04-27 CA CA2760096A patent/CA2760096C/en not_active Expired - Fee Related
- 2010-04-27 ES ES10721856.2T patent/ES2684696T3/es active Active
- 2010-04-27 US US13/265,252 patent/US10117930B2/en active Active
- 2010-04-27 JP JP2012507877A patent/JP5740390B2/ja not_active Expired - Fee Related
- 2010-04-27 EP EP10721856.2A patent/EP2424890B1/en not_active Not-in-force
- 2010-04-27 KR KR1020117027634A patent/KR101785120B1/ko not_active Expired - Fee Related
- 2010-04-27 EA EA201171304A patent/EA024697B1/ru not_active IP Right Cessation
- 2010-04-27 DK DK10721856.2T patent/DK2424890T3/en active
- 2010-04-27 AU AU2010243205A patent/AU2010243205B2/en active Active
- 2010-04-27 SG SG2011073582A patent/SG175142A1/en unknown
- 2010-04-27 CA CA3017477A patent/CA3017477A1/en not_active Abandoned
- 2010-04-27 EP EP18185733.5A patent/EP3461840A1/en not_active Withdrawn
- 2010-04-27 BR BRPI1014774-8A patent/BRPI1014774A2/pt not_active Application Discontinuation
- 2010-04-27 MX MX2011011376A patent/MX2011011376A/es unknown
- 2010-04-27 WO PCT/IL2010/000339 patent/WO2010125565A2/en not_active Ceased
-
2011
- 2011-10-25 IL IL215924A patent/IL215924B/en active IP Right Grant
-
2018
- 2018-11-02 US US16/179,696 patent/US20190209681A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525376A5 (https=) | ||
| Wang et al. | Systematic review: chronic viral hepatitis and metabolic derangement | |
| EA201391262A1 (ru) | Композиция, способ лечения и диагностики стеатоза печени как самостоятельного заболевания или в комбинации с инфекцией гепатита с | |
| Douglas et al. | Oxidative stress attenuates lipid synthesis and increases mitochondrial fatty acid oxidation in hepatoma cells infected with hepatitis C virus | |
| Sun et al. | Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection | |
| Cheng et al. | Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy? | |
| BR112013027479A2 (pt) | "usos de um composto ou de um oligonucleotídeo modificado dirigidos a apociii, e medicamento compreendendo o referido composto" | |
| SMT201500132B (it) | Trattamento dell'infezione da virus dell'epatite bda solo o in combinazione con virus dell'epatite delta e delle patologie epatiche associate | |
| JP2017515854A5 (https=) | ||
| JP2016530279A5 (https=) | ||
| WO2015003122A3 (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
| JP2010520200A5 (https=) | ||
| Arain et al. | A comparative study of serum lipid contents in pre and post IFN-alpha treated acute hepatitis C patients | |
| HRP20211727T1 (hr) | Liječenja nealkoholnog steatohepatitisa (nash) | |
| Ersöz et al. | Ornidazole-induced autoimmune hepatitis | |
| JP2015209424A5 (https=) | ||
| JP2012102100A5 (https=) | ||
| 하연김 et al. | A case report of nonalcoholic steatohepatitis with metabolic Syndrome | |
| WO2010081095A3 (en) | Methods and compositions for inhibiting hepatitis c virus replication | |
| Wang et al. | NKT cells in liver fibrosis: Controversies or complexities | |
| 李佳美 | The activation of NLRP3 inflammasome involved in the decrease of BDNF induced by CUMS | |
| 许刚 et al. | MiR-221 accentuates IFN's anti-HCV effect by downregulating SOCS1 and SOCS3 | |
| Wang et al. | THE EFFICACY OF INDIVIDUALIZED PEGINTERFERON ALFA-2A THERAPY AND ITS INFLUENCE ON HISTOLOGICAL RESPONSE IN THE MANAGEMENT OF HBEAG-POSITIVE CHB PATIENTS: 239 | |
| Feitelson | Putative mechanisms of hepatitis B and hepatitis C viruses in the pathogenesis of hepatocellular carcinoma (HCC) | |
| Sadhukhan et al. | Elevated Level of Liver Enzymes is not a Serum Marker for Hepatitis C Virus Infection among ß-Thalassemic Individuals |